These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7277186)

  • 21. Effect of trihexyphenidyl, a non-selective antimuscarinic drug, on decarboxylation of L-dopa in hemi-Parkinson rats.
    Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
    Eur J Pharmacol; 1998 Jul; 353(1):33-42. PubMed ID: 9721037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-emetic drug maropitant induces intestinal motility disorder but not anti-inflammatory action in mice.
    Mikawa S; Yamamoto S; Islam MS; Kaji N; Murata T; Mizuno R; Ozaki H; Hori M
    J Vet Med Sci; 2015 Oct; 77(10):1195-9. PubMed ID: 25947563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Domperidone, a novel and safe gastrokinetic anti-nauseant for the treatment of dyspepsia and vomiting.
    Reyntjens AJ; Niemegeers CJ; Van Nueten JM; Laduron P; Heykants J; Schellekens KH; Marsboom R; Jageneau A; Broekaert A; Janssen PA
    Arzneimittelforschung; 1978; 28(7):1194-6. PubMed ID: 582708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Buprenorphine versus domperidone in chemotherapy-induced emesis: a pilot study.
    Dullemond-Westland AC; Neijt JP; Nortier JW; Sitsen JM
    Radiother Oncol; 1986 Jun; 6(2):127-33. PubMed ID: 3526421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of exepanol-HCl, metoclopramide and domperidone on the lower esophageal sphincter of dogs.
    Wolf KU
    Arzneimittelforschung; 1985; 35(1):136-7. PubMed ID: 4039143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist.
    Yoshikawa T; Yoshida N; Oka M
    Br J Pharmacol; 2001 May; 133(2):253-60. PubMed ID: 11350861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dopaminergic modulation of rectosigmoid motility: action of domperidone.
    Wiley J; Owyang C
    J Pharmacol Exp Ther; 1987 Aug; 242(2):548-51. PubMed ID: 3612550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of domperidone in improving intestinal activity in acute myocardial infarction patients.
    Lencz L
    Ther Hung; 1991; 39(3):145-7. PubMed ID: 1818429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative study on the effect of the dopamine receptor blockers metoclopramide and domperidone on stomach emptying and the visualization of the small intestine in monocontrast].
    Stellamor K; Hruby W
    Wien Klin Wochenschr; 1983 Sep; 95(18):649-52. PubMed ID: 6649651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The antiemetic effects of domperidone, a novel potent gastrokinetic.
    Niemegeers CJ; Schellekens KH; Janssen PA
    Arch Int Pharmacodyn Ther; 1980 Mar; 244(1):130-40. PubMed ID: 7416883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of anticholinergic drugs on gastro-intestinal absorption of L-dopa in rats and in man.
    Algeri S; Cerletti C; Curcio M; Morselli PL; Bonollo L; Buniva G; Minazzi M; Minoli G
    Eur J Pharmacol; 1976 Feb; 35(2):293-9. PubMed ID: 1248506
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs.
    Costall B; Domeney AM; Naylor RJ; Tattersall FD
    Neuropharmacology; 1987 Sep; 26(9):1321-6. PubMed ID: 2890117
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Muscarinic antagonists in substantia nigra influence the decarboxylation of L-dopa in striatum.
    Izurieta-Sánchez P; Sarre S; Ebinger G; Michotte Y
    Eur J Pharmacol; 2000 Jul; 399(2-3):151-60. PubMed ID: 10884514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuropharmacological mechanisms of emesis. I. Effects of antiemetic drugs on motion- and apomorphine-induced pica in rats.
    Takeda N; Hasegawa S; Morita M; Horii A; Uno A; Yamatodani A; Matsunaga T
    Methods Find Exp Clin Pharmacol; 1995 Nov; 17(9):589-90. PubMed ID: 8786672
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Domperidone and levodopa in Parkinson's disease.
    Shindler JS; Finnerty GT; Towlson K; Dolan AL; Davies CL; Parkes JD
    Br J Clin Pharmacol; 1984 Dec; 18(6):959-62. PubMed ID: 6529536
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of domperidone as a modifier of gamma-radiation-induced emesis.
    Cordts RE; Yochmowitz MG; Hardy KA
    Int J Radiat Oncol Biol Phys; 1987 Sep; 13(9):1333-7. PubMed ID: 3624041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Motilium with gastrokinetic and anti-emetic action in outpatients.
    Porkoláb E
    Ther Hung; 1988; 36(3):132-5. PubMed ID: 3250001
    [No Abstract]   [Full Text] [Related]  

  • 38. Dopamine-induced protection against indomethacin-evoked intestinal lesions in rats--role of anti-intestinal motility mediated by D2 receptors.
    Miyazawa T; Matsumoto M; Kato S; Takeuchi K
    Med Sci Monit; 2003 Feb; 9(2):BR71-7. PubMed ID: 12601282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L-646,462, a cyproheptadine-related antagonist of dopamine and serotonin with selectivity for peripheral systems.
    Williams M; Martin GE; Remy DC; Hichens M; Mangel AW; Taylor DA; Yarbrough GG; Bendesky RJ; King SW; Robinson JL
    J Pharmacol Exp Ther; 1984 Jun; 229(3):775-81. PubMed ID: 6547178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of dopamine D2 receptor antagonists on gastrointestinal motility].
    Mizumoto A; Ito A
    Nihon Heikatsukin Gakkai Zasshi; 1990 Apr; 26(2):65-9. PubMed ID: 2273688
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.